niacinamide and Peripheral Nerve Diseases

niacinamide has been researched along with Peripheral Nerve Diseases in 11 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Research

Studies (11)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Difference in Score Between Baseline and End of Treatment for the FACT&GOG-NTX Subscale .

Difference in Score on the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity questionnaire at the end of treatment; i.e. Score at screening - score at end of treatment. This questionnaire asks 11 questions that are specific to chemotherapy-induced peripheral neuropathies. Maximum score is 44, minimum score is 0. Positive differences indicate a decrease in neuropathy. Negative differences indicate a worsening of neuropathy. Zero means unchanged. (NCT03642990)
Timeframe: 4 weeks

Difference in Total Neuropathy Score Between Screening and End of Treatment

Exploratory analysis of ability of the clinical version of the Total Neuropathy Score questionnaire to detect changes in CIPN severity over time. Unlike the CTCAE or the FACT&GOG-NTX questionnaires, the TNS is a patient reported outcome measure. HIghest score (worse neuropathy is 24, lowest score is 0. Outcome assessed difference between end of treatment and screening. A positive number indicates improvement in neuropathy (NCT03642990)
Timeframe: 4 weeks

Number of Dose Reduction Events

Count the number of (i.e. the incidence) of dose reduction events due to neuropathy (each occasion of dose reduction is a separate event); (NCT03642990)
Timeframe: 3 weeks

Number of Participants With No Worsening in the Grade of Peripheral Sensory Neuropathy as Scored by CTCAE

"The primary outcome variable is defined as no worsening of the grade of peripheral sensory neuropathy as scored according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 guidelines. Per the CTCAE a score of 1 would be assigned in the instance of parethesias or a loss of deep tendon reflexes. A score of 2 would be assigned in the instance of moderate symptoms that limit instrumental activities of daily living. A score of 3 would be assigned in the instance of severe symptoms that limit self-care activities of daily living. Because the outcome measure is defined as no worsening of the grade, it was recorded as either yes( i.e. it worsened) or no (i.e. it did not worsen)." (NCT03642990)
Timeframe: approximately 4 weeks

Percentage of Patients in Which Dose of Paclitaxel or Nab-Paclitaxel is Reduced Due to CIPN

Quantitate the percentage of patients that experience a dose reduction of paclitaxel or nab-paclitaxel therapy due to neuropathy. (NCT03642990)
Timeframe: 3 weeks

Plasma Concentration of Paclitaxel After NIAGEN Treatment Began

Paclitaxel levels in plasma were measured ~30 min after each infusion of taxane. This was undertaken to ascertain whether NIAGEN altered plasma levels of paclitaxel because increases or decreases in plasma levels of paclitaxel by itself could lead to an apparent worsening or improvement, respectively, in CIPN and confound interpretation of NIAGEN's effect. (NCT03642990)
Timeframe: up to 3 weeks

Total Dose of Paclitaxel Administered

Quantitate the total cumulative dose of paclitaxel administered over the 12 weeks. (NCT03642990)
Timeframe: 3 weeks

Reviews

2 reviews available for niacinamide and Peripheral Nerve Diseases

Trials

1 trial available for niacinamide and Peripheral Nerve Diseases

Other Studies

8 other studies available for niacinamide and Peripheral Nerve Diseases